Research ExplorerPublicationsObesity paradox in prostate cancer: increased body mass inde...

Obesity paradox in prostate cancer: increased body mass index was associated with decreased risk of metastases after surgery in 13,667 patients

Standard

Obesity paradox in prostate cancer: increased body mass index was associated with decreased risk of metastases after surgery in 13,667 patients. / Schiffmann, Jonas; Karakiewicz, Pierre I; Rink, Michael; Manka, L; Salomon, Georg; Tilki, Derya; Budäus, Lars; Pompe, Raisa; Leyh-Bannurah, Sami-Ramzi; Haese, Alexander; Hammerer, P; Huland, Hartwig; Graefen, Markus; Tennstedt, Pierre.

In: WORLD J UROL, Vol. 36, No. 7, 07.2018, p. 1067-1072.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Schiffmann, J, Karakiewicz, PI, Rink, M, Manka, L, Salomon, G, Tilki, D, Budäus, L, Pompe, R, Leyh-Bannurah, S-R, Haese, A, Hammerer, P, Huland, H, Graefen, M & Tennstedt, P 2018, 'Obesity paradox in prostate cancer: increased body mass index was associated with decreased risk of metastases after surgery in 13,667 patients', WORLD J UROL, vol. 36, no. 7, pp. 1067-1072. https://doi.org/10.1007/s00345-018-2240-8

APA

Schiffmann, J., Karakiewicz, P. I., Rink, M., Manka, L., Salomon, G., Tilki, D., Budäus, L., Pompe, R., Leyh-Bannurah, S-R., Haese, A., Hammerer, P., Huland, H., Graefen, M., & Tennstedt, P. (2018). Obesity paradox in prostate cancer: increased body mass index was associated with decreased risk of metastases after surgery in 13,667 patients. WORLD J UROL, 36(7), 1067-1072. https://doi.org/10.1007/s00345-018-2240-8

Vancouver

Schiffmann J, Karakiewicz PI, Rink M, Manka L, Salomon G, Tilki D et al. Obesity paradox in prostate cancer: increased body mass index was associated with decreased risk of metastases after surgery in 13,667 patients. WORLD J UROL. 2018 Jul;36(7):1067-1072. https://doi.org/10.1007/s00345-018-2240-8

Bibtex

@article{81729ab4d03345cb9485afac4ed5ca4e,
title = "Obesity paradox in prostate cancer: increased body mass index was associated with decreased risk of metastases after surgery in 13,667 patients",
abstract = "INTRODUCTION: Obesity might negatively affect prostate cancer (PCa) outcomes. However, evidence according to the associations between obesity and metastases-free survival after radical prostatectomy (RP) is still inconsistent.METHODS: We relied on PCa patients treated with RP at the Martini-Klinik Prostate Cancer Center between 2004 and 2015. First, multivariable Cox regression analyses examined the impact of obesity on metastases after RP. Last, in a propensity score matched cohort, Kaplan-Meier analyses assessed metastases-free survival according to body mass index (kg/m2) (BMI) strata (≥ 30 vs. < 25).RESULTS: Of 13,667 individuals, 1990 (14.6%) men were obese (BMI ≥ 30). Median follow-up was 36.4 month (IQR 13.3-60.8). Obese patients were less likely to exhibit metastases after RP (HR 0.7, 95% CI 0.5-0.97, p = 0.03). Similarly, after propensity score adjustment, obesity was associated with increased metastases-free survival (log rank p = 0.001).CONCLUSION: We recorded the obesity paradox phenomenon in PCa patients. In particular, high BMI (≥ 30) was associated with decreased risk of metastases after RP, despite an increased risk being anticipated. Whether statin use might have affected the results was not assessed. Further research is needed to unravel the controversially debated association between obesity and PCa.",
keywords = "Journal Article",
author = "Jonas Schiffmann and Karakiewicz, {Pierre I} and Michael Rink and L Manka and Georg Salomon and Derya Tilki and Lars Bud{\"a}us and Raisa Pompe and Sami-Ramzi Leyh-Bannurah and Alexander Haese and P Hammerer and Hartwig Huland and Markus Graefen and Pierre Tennstedt",
year = "2018",
month = jul,
doi = "10.1007/s00345-018-2240-8",
language = "English",
volume = "36",
pages = "1067--1072",
journal = "WORLD J UROL",
issn = "0724-4983",
publisher = "Springer",
number = "7",

}

RIS

TY - JOUR

T1 - Obesity paradox in prostate cancer: increased body mass index was associated with decreased risk of metastases after surgery in 13,667 patients

AU - Schiffmann, Jonas

AU - Karakiewicz, Pierre I

AU - Rink, Michael

AU - Manka, L

AU - Salomon, Georg

AU - Tilki, Derya

AU - Budäus, Lars

AU - Pompe, Raisa

AU - Leyh-Bannurah, Sami-Ramzi

AU - Haese, Alexander

AU - Hammerer, P

AU - Huland, Hartwig

AU - Graefen, Markus

AU - Tennstedt, Pierre

PY - 2018/7

Y1 - 2018/7

N2 - INTRODUCTION: Obesity might negatively affect prostate cancer (PCa) outcomes. However, evidence according to the associations between obesity and metastases-free survival after radical prostatectomy (RP) is still inconsistent.METHODS: We relied on PCa patients treated with RP at the Martini-Klinik Prostate Cancer Center between 2004 and 2015. First, multivariable Cox regression analyses examined the impact of obesity on metastases after RP. Last, in a propensity score matched cohort, Kaplan-Meier analyses assessed metastases-free survival according to body mass index (kg/m2) (BMI) strata (≥ 30 vs. < 25).RESULTS: Of 13,667 individuals, 1990 (14.6%) men were obese (BMI ≥ 30). Median follow-up was 36.4 month (IQR 13.3-60.8). Obese patients were less likely to exhibit metastases after RP (HR 0.7, 95% CI 0.5-0.97, p = 0.03). Similarly, after propensity score adjustment, obesity was associated with increased metastases-free survival (log rank p = 0.001).CONCLUSION: We recorded the obesity paradox phenomenon in PCa patients. In particular, high BMI (≥ 30) was associated with decreased risk of metastases after RP, despite an increased risk being anticipated. Whether statin use might have affected the results was not assessed. Further research is needed to unravel the controversially debated association between obesity and PCa.

AB - INTRODUCTION: Obesity might negatively affect prostate cancer (PCa) outcomes. However, evidence according to the associations between obesity and metastases-free survival after radical prostatectomy (RP) is still inconsistent.METHODS: We relied on PCa patients treated with RP at the Martini-Klinik Prostate Cancer Center between 2004 and 2015. First, multivariable Cox regression analyses examined the impact of obesity on metastases after RP. Last, in a propensity score matched cohort, Kaplan-Meier analyses assessed metastases-free survival according to body mass index (kg/m2) (BMI) strata (≥ 30 vs. < 25).RESULTS: Of 13,667 individuals, 1990 (14.6%) men were obese (BMI ≥ 30). Median follow-up was 36.4 month (IQR 13.3-60.8). Obese patients were less likely to exhibit metastases after RP (HR 0.7, 95% CI 0.5-0.97, p = 0.03). Similarly, after propensity score adjustment, obesity was associated with increased metastases-free survival (log rank p = 0.001).CONCLUSION: We recorded the obesity paradox phenomenon in PCa patients. In particular, high BMI (≥ 30) was associated with decreased risk of metastases after RP, despite an increased risk being anticipated. Whether statin use might have affected the results was not assessed. Further research is needed to unravel the controversially debated association between obesity and PCa.

KW - Journal Article

U2 - 10.1007/s00345-018-2240-8

DO - 10.1007/s00345-018-2240-8

M3 - SCORING: Journal article

C2 - 29497861

VL - 36

SP - 1067

EP - 1072

JO - WORLD J UROL

JF - WORLD J UROL

SN - 0724-4983

IS - 7

ER -